Skin Manifestations: Clinical Trials

1,505 trials for Skin Manifestations, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

838 completed, 242 unknown, 154 recruiting, 85 terminated. 396 Not applicable, 368 Phase 2, 269 Phase 3, 139 Phase 1, 102 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable396Completed 241, Unknown 65, Recruiting 29, Not yet recruiting 27, Terminated 11, Active not recruiting 8, Withdrawn 8, Enrolling by invitation 4, Suspended 3
Phase 2368Completed 175, Unknown 60, Recruiting 46, Terminated 38, Not yet recruiting 20, Withdrawn 17, Active not recruiting 12
Phase 3269Completed 172, Unknown 31, Recruiting 19, Terminated 17, Withdrawn 16, Active not recruiting 7, Not yet recruiting 7
Phase 1139Completed 75, Recruiting 21, Terminated 15, Not yet recruiting 11, Unknown 10, Withdrawn 4, Active not recruiting 2, Enrolling by invitation 1
Phase 4102Completed 63, Unknown 16, Recruiting 7, Terminated 7, Withdrawn 5, Not yet recruiting 4
Early Phase 123Completed 11, Recruiting 5, Unknown 4, Not yet recruiting 3

Follow Skin Manifestations: new trials by email Literature Review of Skin Manifestations trials Research Report on Skin Manifestations

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruitingNovartis Pharmaceuticals362027-02-082026-06-25
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
RXIM002 - Immune Thrombocytopenia (ITP)
Phase 1Not yet recruitingRiboX Therapeutics Ltd.272027-02-012026-09-23
Efficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study
Cannabis oil, Placebo - Pruritus
Phase 2Not yet recruitingUniversity Hospital, Brest2182027-01-012026-06-12
Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin
ATTO-1310, Placebo - Chronic Pruritus of Unknown Origin
Phase 2Not yet recruitingAttovia Therapeutics Inc3002026-12-212026-09-22
Topical Minocycline for CARP
Topical Minocycline Foam FXFM244, Control - Confluent and Reticulated Papillomatosis (CARP)
Early Phase 1Not yet recruitingMedical University of South Carolina352026-12-152026-10-22
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation
The Supraglottic Oxygenation Via Oral Transtracheal Catheter Group, The Regular Nasal Cannula - Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice
Not applicableNot yet recruitingZhejiang University4102026-11-122026-09-25
ALDH2 Genetic Testing in East Asian Community
Genetic Test Results Return, Alcohol Flushing Education - Healthy Adult, Flushing
Not applicableNot yet recruitingNorthwestern University1002026-11-012026-08-11
TGD001 Treatment in Thrombotic Microangiopathies
TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Phase 1 / Phase 2Not yet recruitingTargED Biopharmaceuticals B.V.702026-10-312026-09-29
J-LINX: Japan LINerixibat eXtension Study
Linerixibat - Pruritus
Phase 3Not yet recruitingGlaxoSmithKline402026-10-092026-10-06
TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years
TRIDERM D.S. Crema Normalizzante - Cradle Cap, Seborrheic Dermatitis
Not applicableNot yet recruitingICIM International S.r.l.202026-10-012026-10-06
A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies
abrocitinib - Dermatitis, Atopic
Not yet recruitingPfizer1202026-10-012026-10-21
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program
No Intervention - Thrombotic Thrombocytopenic Purpura (TTP)
RecruitingTakeda942026-09-242026-10-20
A Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use
Hybrid sunscreen, Chemical sunscreen, No sunscreen - Epidermis, Ultraviolet Exposure
Phase 4RecruitingGood Molecules, LLC602026-09-142026-08-27
Suprapapillary Versus Transpapillary Plastic Stents for Unresectable Malignant Hilar Biliary Obstruction
Suprapapillary plastic stent placement, Transpapillary plastic stent placement - Biliary Tract Neoplasms, Biliary Drainage
Not applicableNot yet recruitingNational Taiwan University Hospital702026-09-012026-09-10
Selective Mediterranean Diet in Immune Thrombocytopenia
Selective Mediterranean Diet, Standard Pharmacological Therapy for ITP - Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
Not applicableNot yet recruitingAssiut University602026-09-012026-09-03
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
Lebrikizumab - Prurigo Nodularis (PN)
Phase 2Not yet recruitingUniversity of Maryland, Baltimore152026-09-012026-09-03
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
CHT105 - Immune Thrombocytopenia (ITP)
Not applicableNot yet recruitingNanjing Miracle Biotechnology Co., Ltd.242026-09-012026-09-10
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia
Phase 3RecruitingAmgen1262026-08-212026-09-17
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Phase 2RecruitingNovartis Pharmaceuticals1642026-08-042026-10-22

Showing 20 of 1505. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (481)  ·  Pruritus (419)  ·  Erythema (117)  ·  Jaundice (82)  ·  Dermatitis, Atopic (74)  ·  Tinea Pedis (69)  ·  Purpura, Thrombotic Thrombocytopenic (65)  ·  Cellulite (64)  ·  Thrombocytopenia (58)  ·  Jaundice, Obstructive (56)  ·  Eczema (44)  ·  Striae Distensae (42)  ·  Psoriasis (37)  ·  Purpura (36)  ·  Pain (35)

Broader conditions

Signs and Symptoms (1505)  ·  Pathological Conditions, Signs and Symptoms (1504)  ·  Pathologic Processes (864)  ·  Skin and Connective Tissue Diseases (683)  ·  Hemic and Lymphatic Diseases (660)  ·  Immune System Diseases (651)  ·  Skin Diseases (635)  ·  Blood Coagulation Disorders (628)  ·  Hematologic Diseases (626)  ·  Hemorrhage (619)  ·  Purpura (564)  ·  Cytopenia (548)  ·  Blood Platelet Disorders (541)  ·  Thrombotic Microangiopathies (540)

Interventions

eltrombopag (62)  ·  Dexamethasone (51)  ·  Rituximab (48)  ·  romiplostim (34)  ·  Immunoglobulins, Intravenous (19)  ·  avatrombopag (18)  ·  Histamine (17)  ·  Blood Specimen Collection (16)  ·  Prednisone (16)  ·  Sodium Chloride (14)  ·  difelikefalin (13)  ·  Danazol (12)  ·  Tablets (12)  ·  Standard of Care (11)  ·  Thrombopoietin (11)

Sponsors

Peking University People's Hospital (49)  ·  Shandong University (38)  ·  Novartis Pharmaceuticals (34)  ·  GlaxoSmithKline (33)  ·  Institute of Hematology & Blood Diseases Hospital, China (33)  ·  Aalborg University (25)  ·  Assistance Publique - Hôpitaux de Paris (21)  ·  Amgen (20)  ·  Assiut University (20)  ·  Endo USA Inc., a Keenova Therapeutics Company (18)  ·  Sohag University (16)  ·  University Hospital, Brest (15)  ·  Cara Therapeutics, Inc. (14)  ·  Galderma R&D (13)  ·  Pfizer (12)

Countries

United States (495)  ·  China (261)  ·  France (141)  ·  Germany (126)  ·  United Kingdom (114)  ·  Spain (97)  ·  Canada (96)  ·  Italy (92)  ·  Poland (91)  ·  Turkey (Türkiye) (68)  ·  Australia (52)  ·  Netherlands (51)  ·  South Korea (49)  ·  Czechia (44)  ·  Egypt (44)

Top investigators

Lei Zhang, MD (14)  ·  Xiao-Hui Zhang, MD (14)  ·  Xiaohui Zhang, MD (8)  ·  Ming Hou, Dr (6)  ·  Ming Hou (5)  ·  Ming Hou, Dr. (5)  ·  Murad Alam, MD (5)

Results publications

PMID 33283264, PMID 19005182, PMID 32816215, PMID 36853224, PMID 19671919, PMID 24802773, PMID 36039153, PMID 19846889, PMID 26231455, PMID 26688484, PMID 33982267, PMID 33995988, PMID 37968132, PMID 39037824, PMID 11050519, PMID 12944568, PMID 17077333, PMID 18242413, PMID 20546023, PMID 21533818, PMID 22117897, PMID 22409309, PMID 22494019, PMID 22760174, PMID 23293082, PMID 23470153, PMID 23492914, PMID 24254965, PMID 24802775, PMID 25856035, PMID 25971957, PMID 26149717, PMID 26480931, PMID 27734464, PMID 28396102, PMID 29042367, PMID 29536526, PMID 32632956, PMID 33658996, PMID 33840781, PMID 33881463, PMID 33957195, PMID 34452956, PMID 35305260, PMID 36016762, PMID 36264430, PMID 37341961, PMID 37888917, PMID 37953500, PMID 38698175

NIH funding

2023 (16), 2018 (10), 2017 (9), 2019 (9), 2016 (7), 2009 (4), 2015 (4), 2025 (4), 2014 (3), U54AR057319 (3), U01HL072268 (2), 2004 (1), 2008 (1), K01HL173859 (1), P30CA015083 (1)